Leadership Team
A highly experienced team with a strong track record of performance
The ImmVirX team comprises key directors and the executive and scientific staff from Viralytics, a clinical-stage oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million.

Management Team
In the News
View our recent news stories
Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.
View All Stories

ImmVirX presents on its Phase 1a Clinical Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 6, 2023
No Comments
Read More »

